Roche Holding AG Pre-Tax Income 2010-2023 | RHHBY
Roche Holding AG annual/quarterly pre-tax income history and growth rate from 2010 to 2023. Pre-tax income can be defined as company's earnings or loss before taxes on income have been accounted for.
- Roche Holding AG pre-tax income for the quarter ending December 31, 2023 was $M, a NAN% increase year-over-year.
- Roche Holding AG pre-tax income for the twelve months ending December 31, 2023 was $0M, a NAN% increase year-over-year.
- Roche Holding AG annual pre-tax income for 2023 was $15.683B, a 8.34% decline from 2022.
- Roche Holding AG annual pre-tax income for 2022 was $17.109B, a 10.12% decline from 2021.
- Roche Holding AG annual pre-tax income for 2021 was $19.035B, a 0.66% decline from 2020.
Roche Holding AG Annual Pre-Tax Income
(Millions of US $) |
| 2023 |
$15,683 |
| 2022 |
$17,109 |
| 2021 |
$19,035 |
| 2020 |
$19,161 |
| 2019 |
$16,722 |
| 2018 |
$14,465 |
| 2017 |
$12,448 |
| 2016 |
$13,206 |
| 2015 |
$12,475 |
| 2014 |
$13,695 |
| 2013 |
$15,844 |
| 2012 |
$13,150 |
| 2011 |
$13,457 |
| 2010 |
$10,774 |
| 2009 |
$9,450 |
Roche Holding AG Quarterly Pre-Tax Income
(Millions of US $) |
| 2023-12-31 |
|
| 2023-06-30 |
|
| 2022-12-31 |
|
| 2022-06-30 |
|
| 2021-12-31 |
|
| 2021-06-30 |
|
| 2020-12-31 |
|
| 2020-06-30 |
|
| 2019-12-31 |
|
| 2019-06-30 |
|
| 2018-12-31 |
|
| 2018-06-30 |
|
| 2017-12-31 |
|
| 2017-06-30 |
|
| 2016-12-31 |
|
| 2016-06-30 |
|
| 2015-12-31 |
|
| 2015-06-30 |
|
| 2014-12-31 |
|
| 2014-06-30 |
|
| 2013-12-31 |
|
| 2013-06-30 |
|
| 2012-12-31 |
|
| 2012-06-30 |
|
| 2011-12-31 |
|
| 2011-06-30 |
|
| 2010-12-31 |
|
| 2010-06-30 |
|
| 2009-12-31 |
|
| 2009-06-30 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$247.847B |
$65.370B |
|
Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc.
|
